Cytokinetics (CYTK) Competitors $60.72 +0.69 (+1.14%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK vs. BNTX, TEVA, GMAB, SMMT, RDY, ASND, VTRS, ROIV, QGEN, and ELANShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences QIAGEN Elanco Animal Health BioNTech (NASDAQ:BNTX) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment. Is BNTX or CYTK more profitable? BioNTech has a net margin of -12.20% compared to Cytokinetics' net margin of -707.17%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% Cytokinetics -707.17%N/A -45.52% Which has more risk and volatility, BNTX or CYTK? BioNTech has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Do analysts prefer BNTX or CYTK? BioNTech currently has a consensus price target of $134.32, indicating a potential upside of 28.29%. Cytokinetics has a consensus price target of $76.64, indicating a potential upside of 26.21%. Given BioNTech's higher possible upside, equities research analysts clearly believe BioNTech is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64Cytokinetics 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 Which has higher valuation and earnings, BNTX or CYTK? Cytokinetics has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.88B8.74-$719.92M-$1.60-65.44Cytokinetics$85.74M84.75-$589.53M-$5.10-11.91 Does the media favor BNTX or CYTK? In the previous week, Cytokinetics had 30 more articles in the media than BioNTech. MarketBeat recorded 39 mentions for Cytokinetics and 9 mentions for BioNTech. BioNTech's average media sentiment score of 0.71 beat Cytokinetics' score of 0.21 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 7 Very Positive mention(s) 2 Positive mention(s) 24 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in BNTX or CYTK? 15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 2.7% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryBioNTech beats Cytokinetics on 9 of the 17 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.22B$3.34B$6.06B$10.38BDividend YieldN/A2.31%5.73%4.78%P/E Ratio-11.8422.1986.0626.86Price / Sales84.75415.96582.90180.66Price / CashN/A44.9825.7330.17Price / Book-52.8010.3012.686.63Net Income-$589.53M-$52.31M$3.31B$276.12M7 Day Performance0.14%0.15%-0.66%-1.86%1 Month Performance18.77%13.31%8.45%5.63%1 Year Performance10.65%27.02%77.27%32.94% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics3.6282 of 5 stars$60.73+1.1%$76.64+26.2%+9.4%$7.22B$85.74M-11.84250BNTXBioNTech2.151 of 5 stars$98.10+0.0%$134.56+37.2%-15.3%$23.58B$2.98B0.006,772Analyst ForecastTEVATeva Pharmaceutical Industries3.234 of 5 stars$19.17+4.5%$25.14+31.2%+16.0%$21.04B$16.54B7.3436,830Analyst UpgradeGMABGenmab A/S4.2821 of 5 stars$29.33+0.9%$40.00+36.4%+35.2%$18.65B$3.12B17.002,682Analyst RevisionHigh Trading VolumeSMMTSummit Therapeutics2.7669 of 5 stars$21.16+1.0%$31.29+47.9%+7.0%$15.56B$700K0.00110RDYDr. Reddy's Laboratories2.5215 of 5 stars$13.96-1.9%$16.95+21.5%-8.4%$11.87B$3.81B21.1427,811ASNDAscendis Pharma A/S3.0241 of 5 stars$191.60-0.2%$244.36+27.5%+62.6%$11.83B$393.54M-37.131,017Analyst ForecastVTRSViatris1.9474 of 5 stars$9.62+1.1%$10.40+8.1%-14.4%$11.10B$14.74B3.9532,000Positive NewsROIVRoivant Sciences3.3469 of 5 stars$15.10-0.5%$19.94+32.0%+34.8%$10.36B$29.05M0.00860QGENQIAGEN4.3745 of 5 stars$43.880.0%$49.69+13.2%+9.9%$9.76B$1.98B18.715,765Analyst DowngradeELANElanco Animal Health2.5745 of 5 stars$19.63+0.1%$18.33-6.6%+37.6%$9.74B$4.44B22.829,000 Related Companies and Tools Related Companies BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Roivant Sciences Alternatives QIAGEN Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTK) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
